Table 4.
Toxicity possibly, probably, or definitely related to mDCF and trastuzumab (n = 26)
| Any Grade n (%) | Grade 3–4 n (%) | |
|---|---|---|
| Non-hematologic | ||
| Fatigue | 13 (50) | 6 (23) |
| Hypophosphatemia | 4 (15) | 4 (15) |
| Hypokalemia | 5 (19) | 3 (11.5) |
| Hyponatremia | 6 (23) | 1 (4) |
| Hyperglycemia | 7 (27) | 1 (4) |
| Hypersensitivity reaction | 8 (31) | 3 (11.5) |
| Dehydration | 5 (19) | 3 (11.5) |
| Diarrhea | 10 (38) | 2 (8) |
| Gl hemorrhage | 2 (8) | 2 (8) |
| Anorexia | 3 (11.5) | 1 (4) |
| Hyperbilirubinemia | 3 (11.5) | 1 (4) |
| Hypoalbuminemia | 2 (8) | 1 (4) |
| Epiphora | 7 (27) | 1 (4) |
| Nausea | 11 (42) | 1 (4) |
| Syncope | 1 (4) | 1 (4) |
| Thromboembolism | 2 (8) | 1 (4) |
| Hematologic | ||
| Neutropenia | 16 (62) | 11 (42) |
| Lymphopenia | 8 (31) | 8 (31) |
| Anemia | 17 (65) | 7 (27) |
| Thrombocytopenia | 13 (50) | 1 (4) |
Abbreviation: GI, gastrointestinal.